Evidence map›Paper›PMID 30007867›Full record

ArticleSchizophrenia research2018

Olfactory deficits and psychosis-spectrum symptoms in 22q11.2 deletion syndrome.

Sunny X Tang, Paul J Moberg, James J Yi, Andrew S Wiemken, Erich M Dress, Tyler M Moore, Monica E Calkins, Donna M McDonald-McGinn, Elaine H Zackai, Beverly S Emanuel and 3 more

Open access · greenAbstract read
In one paragraph

Article in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sunny X TangUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America. Electronic address: suntang@pennmedicine.upenn.edu.
Paul J MobergUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
James J YiUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America; Children's Hospital of Philadelphia, Department of Child and Adolescent Psychiatry, United States of America.
Andrew S WiemkenUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Erich M DressUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Tyler M MooreUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Monica E CalkinsUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Donna M McDonald-McGinnChildren's Hospital of Philadelphia, Division of Human Genetics, United States of America; University of Pennsylvania, Perelman School of Medicine, Department of Pediatrics, United States of America.
Elaine H ZackaiChildren's Hospital of Philadelphia, Division of Human Genetics, United States of America; University of Pennsylvania, Perelman School of Medicine, Department of Pediatrics, United States of America.
Beverly S EmanuelChildren's Hospital of Philadelphia, Division of Human Genetics, United States of America; University of Pennsylvania, Perelman School of Medicine, Department of Pediatrics, United States of America.
Ruben C GurUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
Raquel E GurUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America; Children's Hospital of Philadelphia, Department of Child and Adolescent Psychiatry, United States of America.
Bruce I TuretskyUniversity of Pennsylvania, Perelman School of Medicine, Department of Psychiatry, United States of America.
University of Pennsylvania · USChildren's Hospital of Philadelphia · US

Funding

SCHIZOPHRENIA: A NEUROPSYCHIATRIC PERSPECTIVET32MH019112 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 1990 to 2024
$6.2M
Olfactory Neuroimaging Markers of Heightened Developmental Risk for SchizophreniaR01MH099156 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI TURETSKY, BRUCE I · 2013 to 2017
$2.9M
A Prospective Study of Endophenotypes in At-Risk Youths and Their SiblingsK08MH079364 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI CALKINS, MONICA E · 2007 to 2011
$750k
NIMH NIH HHS K08 MH079364NIMH NIH HHS L30 MH111007NIMH NIH HHS R01 MH099156NIMH NIH HHS T32 MH019112
6 · The paper itself

Abstract

Olfactory functioning is a promising biomarker for psychosis in 22q11.2 deletion syndrome (22q11DS) but has not been well studied to date. This is a pilot effort to evaluate the potential for tests of olfactory functioning to contribute to risk and resilience prediction in 22q11DS, and is the first study to evaluate relationships among olfactory deficits, cognition and psychosis-spectrum symptoms. Odor identification and discrimination were evaluated in 32 individuals with 22q11DS and 110 healthy comparison subjects (HC). Individuals with 22q11DS also underwent cognitive testing with the Penn Computerized Neurocognitive Battery, which evaluates executive functioning, episodic memory, complex cognition, and social cognition. Positive, negative, disorganized and general psychosis-spectrum symptoms were rated according to the Scale of Prodromal Symptoms. Age-normalized scores were calculated for odor identification and discrimination based on normative data. Both odor identification (p < 0.001, Cohen's d = -2.15, 95% CI [-2.62, -1.68]) and discrimination (p < 0.001, Cohen's d = -1.81, 95% CI [-2.26, -1.35]) were significantly impaired in 22q11DS relative to HC. There were no sex differences in either group. Neither odor identification nor discrimination was correlated with overall cognition or any specific cognitive domain in 22q11DS. Impairment in odor discrimination was correlated with higher negative and overall psychosis-spectrum symptoms. There was no significant effect of catechol-O-methyltransferase Val(158)Met genotype or presence of velopharyngeal insufficiency on olfactory functioning. Olfactory deficits, particularly olfactory discrimination, are robust in 22q11DS and appear to be independent of cognitive deficits. They are also clinically relevant and related to psychosis-spectrum symptoms. Olfactory functioning appears to be a promising biomarker for psychosis in 22q11DS.

Indexed as

22q11 Deletion SyndromeAdolescentAdultBiomarkersChildCognitive DysfunctionFemaleHumansMaleOlfaction DisordersPilot ProjectsPsychotic DisordersYoung AdultBiomarkers22q11.2 deletion syndromeOlfactionPsychosisSchizophrenia

Identifiers

PMID30007867
PMCPMC6432914
OpenAlexW2825835432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.